What is new in the treatment of breast cancer? Read our breast cancer blog and learn more about the latest advancements in the treatment of breast cancer, including PARP inhibitors, CDK 4/6 inhibitors, endocrine therapy, chemotherapy, and immunotherapy.

Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

On 14 December 2018, the FDA approved the Herceptin®-biosimilar Herzuma® (trastuzumab-pkrb, Celltrion), a HER2/neu receptor antagonist, for patients with HER2-overexpressing (HER2+) breast cancer. Herzuma® was approved as biosimilar, not as an interchangeable product.

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

UPPSALA, Sweden, Nov. 21, 2018 /PRNewswire/ — Using the synthetic and fully resorbable TIGR®Matrix surgical mesh (Novus Scientific AB, Uppsala — Sweden) improves the outcome in breast cancer patients undergoing immediate reconstruction, as published in the Journal of Plastic Surgery and Hand Surgery.

PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

On October 16, 2018, the FDA approved PARP-inhibitor talazoparib (Talzenna®, Pfizer) for use in patients with deleterious or suspected deleterious germline BRCA-mutated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Patients should be selected for the PARP inhibitor (PARPi)-treatment using an FDA-approved companion diagnostic (CDx) for talazoparib.

Early breast cancer treatment in China remains conservative

Early breast cancer treatment in China remains conservative

Breast-conserving surgery is uncommon in China, and despite routinely performing SLNB the uptake of the ACOSOG Z0011 study recommendation to treat selected sentinel node-positive patients with whole breast irradiation and adjuvant systemic therapy instead of ALND remains low at only 17% of Chinese centres. These were the key findings of a national survey among 520 Chinese hospitals.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Talazoparib in advanced breast cancer patients with a germline BRCA1:2 mutation

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

Single-agent PARP-inhibition with talazoparib is associated with an improved progression-free survival (PFS) and better patient-reported outcomes (PRO) when compared to chemotherapy alone in patients with advanced breast cancer (ABC) and a germline BRCA1/2 mutation, as reported by the investigators of the Phase III EMBRACA study (NCT01945775) in the New England Journal of Medicine.

Ribociclib FDA label updated to include pre- and perimenopausal women

On July 18, 2018, the US FDA expanded the ribociclib (Kysqali©, Novartis)  approval. Ribociclib plus an aromatase inhibitor as initial endocrine-based therapy is no longer limited to postmenopausal HR-positive, HER2-negative advanced or metastatic breast cancer patients alone and now includes pre- and perimenopausal women. Furthermore, the FDA has added the combination ribociclib plus fulvestrant as initial endocrine-based therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

Breast cancer: a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of options to offer their patients. The American Society of Clinical Oncology’s (ASCO) 2018 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.

HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

Can chemotherapy be avoided in women with hormone-sensitive breast cancer? This is a prominent question in the treatment of breast cancer around the globe.

adjuvant hormonal therapy

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

One in six women with early, operable breast cancer may not need years of adjuvant hormonal therapy after primary treatment. This was the conclusion of a recent study published in JAMA (the Journal of the American Medical Association) Oncology.